Does Prenatal Exercise Affect Maternal Blood Lactate?
A secondary analysis finds prenatal exercise blunts the gestational rise in resting maternal lactate, most in women with overweight or obesity. PICO summary and expert commentary.
Practice-changing landmark trials in endocrinology and metabolism, organized for rapid clinical review, exam preparation, teaching, and evidence-based patient care.
A secondary analysis finds prenatal exercise blunts the gestational rise in resting maternal lactate, most in women with overweight or obesity. PICO summary and expert commentary.
Three-year REAL4 extension data on once-weekly somapacitan versus daily growth hormone in children with growth hormone deficiency, with PICO summary and expert commentary.
A randomized controlled trial found progestin-primed ovarian stimulation and the GnRH antagonist protocol produced statistically similar euploidy rates in PGT-A cycles. PICO summary and expert commentary.
A 103-patient randomized trial tested an extra 25 mcg of levothyroxine during Ramadan against standard weight-based dosing in hypothyroidism. PICO summary and expert commentary.
A 12-week randomized controlled trial found light-to-moderate aerobic walking produced no significant between-group change in bone turnover markers versus inactive controls in postmenopausal osteopenia, with functional gains reported. PICO summary and expert commentary.
A 43-patient single-centre open-label RCT found clinical pharmacist review reduced drug-related problems within the intervention arm but showed no significant between-group difference in overall levothyroxine adherence. PICO summary and expert commentary.
A 24-week double-blind feasibility trial (n=12) found LT4 monotherapy did not normalize free T4 and total T3 after thyroidectomy while LT4-LT3 did, but weight and cholesterol differences were non-significant. PICO summary and expert commentary.
The phase 3 PaTHway trial finds TransCon PTH frees most adults with hypoparathyroidism from conventional therapy and halves urinary calcium. PICO summary and expert commentary.
A phase 3 trial finds recombinant human TSH non-inferior to thyroid hormone withdrawal for radioiodine ablation in intermediate-risk thyroid cancer, with fewer adverse events. PICO summary and commentary.